PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
35507739-0	2022	Maralixibat for the treatment of PFIC: Long-term, IBAT inhibition in an open-label, Phase 2 study.	Lopixibat	0-11	solute carrier family 10 member 2	Homo sapiens	50-54
29284646-6	2018	We report a multidrug regimen of 4-phenylbutyrate, oxcarbazepine, and maralixibat (an experimental drug owned by Shire Pharmaceuticals, Dublin, Republic of Ireland) that completely controlled symptoms in 2 siblings with partial loss of BSEP activity.	Lopixibat	70-81	ATP binding cassette subfamily B member 11	Homo sapiens	236-240
32653991-9	2020	The clinical programs of 2 IBAT inhibitors in development for the treatment of pediatric cholestatic liver diseases, maralixibat and odevixibat, are highlighted.	Lopixibat	117-128	solute carrier family 10 member 2	Homo sapiens	27-31
35507739-3	2022	INDIGO was an open-label, Phase 2, international, long-term study to assess the efficacy and safety of maralixibat in children with FIC1 or BSEP deficiencies.	Lopixibat	103-114	ATPase phospholipid transporting 8B1	Homo sapiens	132-136
35507739-3	2022	INDIGO was an open-label, Phase 2, international, long-term study to assess the efficacy and safety of maralixibat in children with FIC1 or BSEP deficiencies.	Lopixibat	103-114	ATP binding cassette subfamily B member 11	Homo sapiens	140-144
34813049-1	2022	Maralixibat (Livmarli ) is an orally-administered, small-molecule ileal bile acid transporter (IBAT) inhibitor being developed by Mirum Pharmaceuticals for the treatment of rare cholestatic liver diseases including Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC) and biliary atresia.	Lopixibat	0-11	solute carrier family 10 member 2	Homo sapiens	95-99
34813049-1	2022	Maralixibat (Livmarli ) is an orally-administered, small-molecule ileal bile acid transporter (IBAT) inhibitor being developed by Mirum Pharmaceuticals for the treatment of rare cholestatic liver diseases including Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC) and biliary atresia.	Lopixibat	0-11	ATPase phospholipid transporting 8B1	Homo sapiens	288-292